Shield Therapeutics plc
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the…more
Shield Therapeutics plc
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the…more
Latest RNS from Shield Therapeutics plc
- trading_updateQ3 2026 Trading Update
- tvrTotal Voting Rights
- interim_resultsInterim results for the six months ended 30 Jun 26
- trading_updateQ2 and H1 2026 Trading Update
Analyst consensus: Buy
As of 10 Nov 2026, 3 analysts rate Shield Therapeutics plc a Buy, with 100% buy ratings and a mean price target of 16p (range 9p–23p), +376% vs the current price.